RS62430B1 - Tienopiridini i benzotiofeni korisni kao irak4 inhibitori - Google Patents
Tienopiridini i benzotiofeni korisni kao irak4 inhibitoriInfo
- Publication number
- RS62430B1 RS62430B1 RS20211247A RSP20211247A RS62430B1 RS 62430 B1 RS62430 B1 RS 62430B1 RS 20211247 A RS20211247 A RS 20211247A RS P20211247 A RSP20211247 A RS P20211247A RS 62430 B1 RS62430 B1 RS 62430B1
- Authority
- RS
- Serbia
- Prior art keywords
- thienopyridines
- benzothiophenes
- useful
- irak4 inhibitors
- irak4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504956P | 2017-05-11 | 2017-05-11 | |
| PCT/US2018/031945 WO2018209012A1 (en) | 2017-05-11 | 2018-05-10 | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
| EP18727589.6A EP3621960B1 (en) | 2017-05-11 | 2018-05-10 | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS62430B1 true RS62430B1 (sr) | 2021-11-30 |
Family
ID=62245511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20211247A RS62430B1 (sr) | 2017-05-11 | 2018-05-10 | Tienopiridini i benzotiofeni korisni kao irak4 inhibitori |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10829496B2 (sr) |
| EP (1) | EP3621960B1 (sr) |
| JP (1) | JP7154229B2 (sr) |
| KR (1) | KR102604900B1 (sr) |
| CN (1) | CN110612298B (sr) |
| AR (1) | AR111689A1 (sr) |
| AU (1) | AU2018265130B2 (sr) |
| BR (1) | BR112019023290A2 (sr) |
| CA (1) | CA3062602A1 (sr) |
| CL (1) | CL2019003198A1 (sr) |
| CO (1) | CO2019012494A2 (sr) |
| CY (1) | CY1124552T1 (sr) |
| DK (1) | DK3621960T3 (sr) |
| EA (1) | EA039189B1 (sr) |
| ES (1) | ES2889926T3 (sr) |
| HR (1) | HRP20211583T1 (sr) |
| HU (1) | HUE056493T2 (sr) |
| IL (1) | IL270494B (sr) |
| LT (1) | LT3621960T (sr) |
| MX (1) | MX2019012929A (sr) |
| PE (1) | PE20191817A1 (sr) |
| PL (1) | PL3621960T3 (sr) |
| PT (1) | PT3621960T (sr) |
| RS (1) | RS62430B1 (sr) |
| SI (1) | SI3621960T1 (sr) |
| TW (1) | TW201900640A (sr) |
| WO (1) | WO2018209012A1 (sr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| IL307995A (en) | 2017-09-22 | 2023-12-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| CN112105385A (zh) | 2017-12-26 | 2020-12-18 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| CN113423427A (zh) | 2018-11-30 | 2021-09-21 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| WO2021016289A1 (en) * | 2019-07-23 | 2021-01-28 | Bristol-Myers Squibb Company | Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN111285844B (zh) * | 2020-02-24 | 2022-08-12 | 河南师范大学 | 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8627698D0 (en) * | 1986-11-20 | 1986-12-17 | Boots Co Plc | Therapeutic agents |
| ATE432929T1 (de) | 2001-06-15 | 2009-06-15 | Vertex Pharma | 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| WO2004002964A1 (ja) | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
| JP2006516561A (ja) | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類 |
| CA2531401A1 (en) | 2003-07-10 | 2005-01-27 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| MX2007010973A (es) | 2005-03-09 | 2007-09-19 | Schering Corp | Compuestos para inhibir la actividad de cinesina de ksp. |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| TW200806675A (en) | 2006-01-30 | 2008-02-01 | Array Biopharma Inc | Heterobicyclic thiophene compounds and methods of use |
| MX2009013262A (es) | 2007-06-08 | 2010-01-25 | Bayer Cropscience Sa | Derivados de heterociclil-pirimidinil-amino fungicidas. |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| JP5254693B2 (ja) | 2008-07-30 | 2013-08-07 | 三菱重工業株式会社 | Ｎｉ基合金用溶接材料 |
| EP2361902A4 (en) | 2008-11-21 | 2012-04-25 | Astellas Pharma Inc | 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG |
| US8575153B2 (en) | 2008-11-28 | 2013-11-05 | Kowa Company, Ltd. | Pyridine-3-carboxyamide derivative |
| CN102458581B (zh) | 2009-05-22 | 2016-03-30 | 因塞特控股公司 | 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2，3-d]嘧啶和吡咯-3-基-吡咯并[2，3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物 |
| US8586751B2 (en) | 2009-06-12 | 2013-11-19 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| JP2013503903A (ja) | 2009-09-03 | 2013-02-04 | アラーガン インコーポレイテッド | チロシンキナーゼモジュレーターとしての化合物 |
| WO2011053701A1 (en) | 2009-10-30 | 2011-05-05 | Janssen Pharmaceutica Nv | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| JPWO2011093501A1 (ja) | 2010-02-01 | 2013-06-06 | 日本ケミファ株式会社 | Ｇｐｒ１１９作動薬 |
| US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
| RU2013148405A (ru) | 2011-04-29 | 2015-06-10 | Айкан Скул Оф Медисин Эт Маунт Синай | Ингибиторы киназ |
| ES2686500T3 (es) | 2012-01-13 | 2018-10-18 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas |
| JP6096807B2 (ja) | 2012-01-13 | 2017-03-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼ阻害剤として有用なトリアゾリル置換されたピリジル化合物 |
| ES2575604T3 (es) | 2012-01-13 | 2016-06-29 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa |
| AR093403A1 (es) | 2012-11-08 | 2015-06-03 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa |
| WO2014074657A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| KR20150079963A (ko) | 2012-11-08 | 2015-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물 |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| JP6177456B2 (ja) | 2014-04-04 | 2017-08-09 | ファイザー・インク | 二環式縮合ヘテロアリールまたはアリール化合物およびｉｒａｋ４阻害剤としてのそれらの使用 |
| EP3268367B8 (en) * | 2015-03-12 | 2022-11-16 | Merck Sharp & Dohme LLC | Carboxamide inhibitors of irak4 activity |
| EP3268003B1 (en) * | 2015-03-12 | 2020-07-29 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of irak4 activity |
| AR105114A1 (es) | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
| JP6843775B2 (ja) | 2015-06-24 | 2021-03-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリール置換のアミノピリジン化合物 |
| HUE053705T2 (hu) * | 2015-08-27 | 2021-07-28 | Pfizer | Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként |
-
2018
- 2018-05-10 RS RS20211247A patent/RS62430B1/sr unknown
- 2018-05-10 EP EP18727589.6A patent/EP3621960B1/en active Active
- 2018-05-10 PL PL18727589T patent/PL3621960T3/pl unknown
- 2018-05-10 PE PE2019002310A patent/PE20191817A1/es unknown
- 2018-05-10 CA CA3062602A patent/CA3062602A1/en active Pending
- 2018-05-10 HU HUE18727589A patent/HUE056493T2/hu unknown
- 2018-05-10 BR BR112019023290-7A patent/BR112019023290A2/pt not_active Application Discontinuation
- 2018-05-10 PT PT187275896T patent/PT3621960T/pt unknown
- 2018-05-10 KR KR1020197036216A patent/KR102604900B1/ko active IP Right Grant
- 2018-05-10 TW TW107115845A patent/TW201900640A/zh unknown
- 2018-05-10 DK DK18727589.6T patent/DK3621960T3/da active
- 2018-05-10 ES ES18727589T patent/ES2889926T3/es active Active
- 2018-05-10 WO PCT/US2018/031945 patent/WO2018209012A1/en unknown
- 2018-05-10 HR HRP20211583TT patent/HRP20211583T1/hr unknown
- 2018-05-10 LT LTEPPCT/US2018/031945T patent/LT3621960T/lt unknown
- 2018-05-10 US US16/612,478 patent/US10829496B2/en active Active
- 2018-05-10 CN CN201880031240.4A patent/CN110612298B/zh active Active
- 2018-05-10 SI SI201830426T patent/SI3621960T1/sl unknown
- 2018-05-10 AR ARP180101237A patent/AR111689A1/es unknown
- 2018-05-10 EA EA201992674A patent/EA039189B1/ru unknown
- 2018-05-10 AU AU2018265130A patent/AU2018265130B2/en not_active Expired - Fee Related
- 2018-05-10 MX MX2019012929A patent/MX2019012929A/es unknown
- 2018-05-10 JP JP2019561740A patent/JP7154229B2/ja active Active
-
2019
- 2019-11-07 IL IL270494A patent/IL270494B/en unknown
- 2019-11-07 CL CL2019003198A patent/CL2019003198A1/es unknown
- 2019-11-07 CO CONC2019/0012494A patent/CO2019012494A2/es unknown
-
2021
- 2021-10-07 CY CY20211100874T patent/CY1124552T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2019003198A1 (es) | 2020-03-20 |
| JP7154229B2 (ja) | 2022-10-17 |
| AU2018265130B2 (en) | 2022-03-24 |
| AR111689A1 (es) | 2019-08-07 |
| CN110612298A (zh) | 2019-12-24 |
| SI3621960T1 (sl) | 2021-11-30 |
| EA201992674A1 (ru) | 2020-04-06 |
| EA039189B1 (ru) | 2021-12-15 |
| WO2018209012A1 (en) | 2018-11-15 |
| MX2019012929A (es) | 2020-01-14 |
| LT3621960T (lt) | 2021-10-11 |
| CO2019012494A2 (es) | 2020-01-17 |
| IL270494B (en) | 2022-04-01 |
| AU2018265130A1 (en) | 2020-01-02 |
| CN110612298B (zh) | 2023-05-05 |
| BR112019023290A2 (pt) | 2020-06-16 |
| EP3621960A1 (en) | 2020-03-18 |
| EP3621960B1 (en) | 2021-08-04 |
| US10829496B2 (en) | 2020-11-10 |
| PE20191817A1 (es) | 2019-12-27 |
| DK3621960T3 (da) | 2021-09-27 |
| KR20200004871A (ko) | 2020-01-14 |
| HUE056493T2 (hu) | 2022-02-28 |
| CA3062602A1 (en) | 2018-11-15 |
| KR102604900B1 (ko) | 2023-11-21 |
| PT3621960T (pt) | 2021-09-16 |
| PL3621960T3 (pl) | 2021-11-08 |
| CY1124552T1 (el) | 2022-07-22 |
| JP2020519596A (ja) | 2020-07-02 |
| ES2889926T3 (es) | 2022-01-14 |
| US20200062777A1 (en) | 2020-02-27 |
| TW201900640A (zh) | 2019-01-01 |
| HRP20211583T1 (hr) | 2022-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL270494B (en) | Thienopyridines and benzothiophenase are useful as irak4 inhibitors | |
| PL3718370T3 (pl) | Sposoby i powiązane urządzenia służące do realizacji funkcji multi-connectivity | |
| IL269711B (en) | ask1 inhibitory compounds and uses thereof | |
| EP3268003A4 (en) | Thienopyrazine inhibitors of irak4 activity | |
| IL269196A (en) | New inhibitors | |
| FI3672976T3 (fi) | Bcl-2-inhibiittoreita | |
| EP3336091A4 (en) | IRAQ4 INHIBITOR AND ITS USE | |
| SG11202003790PA (en) | Composition and method | |
| SI3621694T1 (sl) | Zaviralci lrrc33 in njihove uporabe | |
| IL274425A (en) | Pyrrolopyrazine derivatives as alpha five integrin inhibitors | |
| EP3336090A4 (en) | INHIBITOR OF IRAQ4 AND ITS USE | |
| ZA201907136B (en) | Ip6k inhibitors | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL263949A (en) | Complement inhibitors and their uses | |
| HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
| IL275935A (en) | Its use and its derivative | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| EP3704104A4 (en) | IRAK4 INHIBITORS AND THEIR USES | |
| PT3725791T (pt) | Sal que serve como inibidor de akt e seu cristal | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL281216A (en) | Inhibitors of glutaminyl cyclase | |
| ZA201904187B (en) | Method and composition | |
| GB201721465D0 (en) | Inhibitors | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors | |
| GB201714238D0 (en) | Composition and method |